Debiopharm has entered into a basic research collaboration with the Experimental Therapeutics Centre (ETC) of Singapore's Agency for Science, Technology and Research (A*STAR), to develop oral small molecule modulators of epigenetic function.
The two sides will co-finance discovery activities and the Swiss firm will carry out subsequent development activities, but additional funding and other financial arrangements